Olympian Bruny Surin Invests in Global Medical Device Company
Currently a brand ambassador for Emovi, Inc. Surin expands partnership as an investor
Montreal, Quebec (September, 2020) – Emovi, Inc. today announced that Canadian Olympian Bruny Surin, a KneeKG™ patient and Emovi Ambassador, has extended his support and became an investor in the company. The advanced partnership will support the organization’s commercialization efforts of the KneeKG. This first in-clinic device meets the global need for measuring knee function with objective and quantifiable data associated with mechanical knee markers and functional deficiencies.
“The Knee Kinesiography with KneeKG has helped tremendously! As a result of my personalized treatment, I went from pain that I rated as ten out of ten, to no pain at all. I fundamentally believe in the benefits of this technology and am very excited to join Emovi as an investor and new partner,” said Bruny Surin.
“I am sincerely delighted to count Bruny among our team of partners,” said Michelle Laflamme, CEO of Emovi. “Since the start of his journey with the KneeKG, he has continuously supported Emovi and has been an exemplary ambassador.”
Continued Laflamme, “The level of confidence that Bruny has in our product further validates the technology and the hard work the team has put into its development. We are thrilled to have Bruny’s support as we continue to advance our product in the market.”
After a long sprinting career, which included a gold medal win in 4×100 meter relay at the 1996 Olympics, Surin began experiencing knee pain in 2014. Despite numerous physiotherapy visits, the pain in his knee remained. After additional evaluations, Surin’s doctor recommended that he complete a Knee Kinesiography with the KneeKG to identify the biomechanical factors causing the pain. The results assisted his doctor in identifying factors related to the progression of knee osteoarthritis (OA), and a personalized treatment program was adapted. All traces of pain were eliminated, allowing him to return to his active lifestyle.
According to Surin, “the biomechanical explanations were related to exactly how I felt. This direct correlation encouraged me to do the suggested exercises. Indeed, a retest showed all the factors related to the progression of OA of the knee had disappeared.”
Still very involved in the world of sport, the former Olympian commented, “this innovative technology is an excellent benefit to the athletes of tomorrow. It not only brings relief from their pain but also ensures the health of their post-career knees.”
The financial terms of this agreement were not disclosed.
About Emovi Inc.
Headquartered in Montreal, Emovi is a medical device company that develops products for knee joint assessment to restore the patient’s quality of life. In partnership with the Quebec university research community, including the CRCHUM, École de Technologie supérieure (ÉTS), and TELUQ, Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi owns multiple patents and the exclusive worldwide license to commercialize KneeKG. http://emovi.ca
The KneeKG is FDA indicated for appropriate assessment of the 3D knee motion for patients who have impaired movement functions of an orthopedic cause. It is intended to provide information used for physical evaluation and treatment planning purposes.